Orchestra BioMedAnnouncementIts GateClinical data on the improvement of cardiac function in hypertensive patients with diastolic dysfunction (DD) through atrioventricular interval modulation (AVIM) therapy published in "JACC: Advances》Journal.

This announcement reveals the results of a retrospective, treatment-blinded analysis of patients from the MODERATO II study. The analysis demonstrates that AVIM therapy significantly reduces systolic blood pressure (SBP) and improves DD echocardiographic markers — key contributors to heart failure with preserved ejection fraction (HFpEF), a common complication in patients with isolated systolic hypertension (ISH).

Specific Research Data

• AVIM therapy significantly reduced office systolic blood pressure (by 12.1±12.8 mmHg) and ambulatory systolic blood pressure (by 8.3±9.7 mmHg) in DD patients within 6 months (p<0.01).

• Key indicators of diastolic function significantly improved in patients treated with AVIM: e′ velocity (increased from 5.9±2.0 to 8.8±3.4 cm/sec) and E/A ratio (increased from 0.86±0.39 to 1.60±0.84), indicating enhanced myocardial relaxation and diastolic compliance.

PI Evaluation

"Long-term hypertension, diastolic dysfunction, and the onset of HFpEF have a clear clinical association, but there is currently a lack of effective interventions. Data from MODERATO II indicates that AVIM therapy, by continuously lowering blood pressure while improving ventricular compliance, has the potential to fill this therapeutic gap. These effects suggest its potential to alter disease progression and reverse cardiac remodeling, which is particularly important for the management of hypertensive heart disease in cardiovascular high-risk patients. As the BACKBEAT study progresses, we look forward to further validating AVIM as a revolutionary therapy that goes beyond blood pressure control."

---Marat Fudim Duke Health

Executive Evaluation

"The progression from uncontrolled hypertension to HFpEF constitutes an increasingly heavy medical burden, particularly in pacemaker-eligible populations with a high incidence of hypertension where treatment options are limited. AVIM therapy, by synchronously targeting elevated systolic blood pressure and diastolic dysfunction, offers a differentiated device-based solution for early intervention in disease progression."JACC: Advances》The results confirm the triple value of AVIM in continuously reducing blood pressure, enhancing cardiac efficiency, and improving myocardial relaxation. We firmly believe that this therapy can not only treat hypertension but also intervene in risk factors for serious cardiovascular events, including HFpEF—diastolic dysfunction.

---Avi Fischer  Orchestra BioMedSenior Vice President of Medical Affairs and Innovation